



ANNEX 1

**Response document for MHRA public consultation on the proposal to make
Acnecide Face Gel and Acnecide Face Wash available from general sales outlets
without prescription**

Ref: ARM 98

Your details

Name: [REDACTED]

Position (if applicable): replying as an individual

Organisation (if applicable): not applicable

Email:

1. Do you consider that Acnecide Face Gel and Acnecide Face Wash should be available as General Sale List (GSL) medicines?

Yes ☒

No ☐

Not sure ☐

Please provide any comments or evidence to support your response:

Benzoyl peroxide has been used worldwide since the 60's.

2. Do you have any specific comments on the leaflets or the labels provided in the public reclassification report for Acnecide Face Gel and Acnecide Face Wash?

No specific comment

3. Do you have any other comments on the reclassification?

No further comment

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes ☐ ~~Partially*~~ ☐

No ☒

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information, we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gov.uk) to arrive by **30 May 2019**. Contributions received after that date cannot be included in the exercise.